<p>生物科技股票可能是投资者感兴趣的一个领域。它们可以在临床试验或 FDA 批准方面的积极消息后带来巨大收益。然而，如果公司的治疗方案出现不利消息或未达预期，也可能导致股价大幅下跌。</p>
<p>在我看来，当投资生物科技行业时，最好避开那些更容易出现股价剧烈波动的小公司。最好选择那些提供多种治疗方案并具有增长潜力的大公司。</p>
<p>在选择当前要购买的生物科技股票时，我选择了那些在过去一年中股价大幅上涨且估值合理的公司，其前瞻市盈率与整个行业相比较低。</p>
<h2>联合治疗（UTHR）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：viewimage / Shutterstock.com</p>
<p><strong>联合治疗</strong>（纳斯达克股票代码：<strong>UTHR</strong>）主要生产和销售与肺部相关的危及生命的疾病的治疗方案，如肺动脉高压。其产品包括 Tyvaso、Remodulin、Adcirca 和 Orenitram。</p>
<p>过去一年，由于其第一季度业绩超出预期，其股价上涨了 40%。</p>
<p>5 月 1 日，联合治疗公布了 2024 年第一季度的财报，称总收入同比增长 34%，净利润同比增长 27%。其旗舰治疗方案中有四种报告显示年度销售增长达两位数。</p>
<p>UTHR 的估值合理，前瞻市盈率为 12.73，而行业中位数前瞻市盈率为 19.61。</p>
<p>由于其多种治疗方案的强劲销售增长，UTHR 为投资者提供上涨潜力。</p>
<h2><strong>奥洛兹美医疗</strong>（HALO）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Microgen / Shutterstock</p>
<p><strong>奥洛兹美医疗</strong>（纳斯达克股票代码：<strong>HALO</strong>）经营一家提供皮下药物递送解决方案以及其他专有酶相关产品的医疗科技平台。</p>
<p>5 月 7 日，奥洛兹美医疗公布了 2024 年第一季度的财报，称总收入同比增长 21%，净利润增长 94%。它还宣布了一项限额为 7.5 亿美元的股票回购计划。</p>
<p>6 月，HALO 更新了其 2024 年全年指导预期，称预期总收入介于 9.35 亿美元至 10.15 亿美元之间。此次指导更新是在其产品 Enhanze 获得专利批准后发布的。</p>
<p>奥洛兹美医疗的前瞻市盈率为 13.34，而行业平均值为 19.61。</p>
<p>HALO 将是投资组合的极佳选择。特别是在最近获得专利批准和提高预期后，它提供了增长潜力。</p>
<h2>安进（AMGN）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Shutterstock</p>
<p><strong>安进</strong>（纳斯达克股票代码：<strong>AMGN</strong>）是一家生产治疗方案的制药公司，其产品包括 Enbrel、Otezla、Prolia、Xgeva 和 Repatha，用于治疗诸如牛皮癣、预防心脏病发作和骨质疏松症等多种问题。它还与其他医疗公司合作开发和销售治疗方案。</p>
<p>在过去一年中，由于其强劲的第一季度业绩报告，其股价上涨了 47%。</p>
<p>5 月 2 日，安进公布了 2024 年第一季度的财报。报告显示，总收入增长 22%，其多款产品的年度销售增长超过两位数，净利润与前一年基本持平。</p>
<p>其股价在其关于潜在减肥药物 MariTide 的正面数据的第一季度业绩报告后大约上涨了 12%。</p>
<p>安进在多款治疗方案中报告了可观的销售增长，预计 2024 年全年总收入将介于 325 亿美元至 338 亿美元之间。对于投资者来说，它是一个稳健的选择；它是一家强劲的生物科技股票，尤其是从长期来看，可以为投资者带来增加的回报。</p>
<p>安进的估值也相当合理。其前瞻市盈率为 16.97，而行业平均值为 19.61。</p>
<p><em>在发布日期，负责编辑在本文中未持有（直接或间接）任何提到的证券。</em></p>
<p><em>截至目前，Noah Bolton 在本文提到的证券中未持有（直接或间接）任何头寸。本文中表达的观点属于作者个人，遵守 InvestorPlace.com 的发布准则。</em></p>
<p>Noah 拥有约一年的自由撰稿经验。他曾与 Investopedia 合作，涉及股市和财经新闻等主题。</p>
<p>生物科技、医疗保健</p>

联合治疗

奥洛兹美医疗

<p>三家生物科技股票可供投资考虑：联合治疗 (UTHR)，奥洛兹美医疗 (HALO) 和安进 (AMGN)。这些公司股价增长强劲，盈利报告积极，并具有增加回报的潜力。建议关注生物科技行业中规模较大的公司，以获得稳定性和增长潜力。这些股票为该领域的投资者提供了机会</p>

<p>Biotech stocks to buy can be an interesting sector for investors. They can provide massive gains following positive news regarding clinical trials or FDA approvals. However, they may also cause large share price drops following bad news or missed expectations surrounding a company’s treatments.</p>
<div class="lb-trans"><p>生物科技股票可能是投资者感兴趣的一个领域。它们可以在临床试验或 FDA 批准方面的积极消息后带来巨大收益。然而，如果公司的治疗方案出现不利消息或未达预期，也可能导致股价大幅下跌。</p>
</div><p>In my opinion, when investing in the biotech industry, it’s best to steer clear of smaller companies that are more susceptible to wild swings in their share price. It is much better to stick with larger companies that offer a wide array of treatments and increased growth potential.</p>
<div class="lb-trans"><p>在我看来，当投资生物科技行业时，最好避开那些更容易出现股价剧烈波动的小公司。最好选择那些提供多种治疗方案并具有增长潜力的大公司。</p>
</div><p>When choosing which biotech stocks to buy right now, I settled on companies that have experienced strong share price appreciation over this past year and a fair valuation, with a low forward P/E ratio compared to the sector overall.</p>
<div class="lb-trans"><p>在选择当前要购买的生物科技股票时，我选择了那些在过去一年中股价大幅上涨且估值合理的公司，其前瞻市盈率与整个行业相比较低。</p>
</div><h2>United Therapeutics (UTHR)</h2>
<div class="lb-trans"><h2>联合治疗（UTHR）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: viewimage / Shutterstock.com</p>
<div class="lb-trans"><p>来源：viewimage / Shutterstock.com</p>
</div><p><strong>United Therapeutics</strong>(NASDAQ: <strong>UTHR</strong>) manufactures and commercializes treatments for life-threatening diseases primarily related to the lungs, such as pulmonary hypertension. Its products include Tyvaso, Remodulin, Adcirca, and Orenitram.</p>
<div class="lb-trans"><p><strong>联合治疗</strong>（纳斯达克股票代码：<strong>UTHR</strong>）主要生产和销售与肺部相关的危及生命的疾病的治疗方案，如肺动脉高压。其产品包括 Tyvaso、Remodulin、Adcirca 和 Orenitram。</p>
</div><p>Over the past year, its share price has increased by 40%, primarily due to its first-quarter earnings beat.</p>
<div class="lb-trans"><p>过去一年，由于其第一季度业绩超出预期，其股价上涨了 40%。</p>
</div><p>On May 1, United Therapeutics reported earnings for the first quarter of 2024, stating that total revenue increased by 34% and net income rose by 27% compared to the previous year. Four of its flagship treatments reported double-digit sales growth year over year.</p>
<div class="lb-trans"><p>5 月 1 日，联合治疗公布了 2024 年第一季度的财报，称总收入同比增长 34%，净利润同比增长 27%。其旗舰治疗方案中有四种报告显示年度销售增长达两位数。</p>
</div><p>UTHR is trading at a fair valuation, with a forward P/E ratio of 12.73, compared to the median sector forward P/E ratio of 19.61.</p>
<div class="lb-trans"><p>UTHR 的估值合理，前瞻市盈率为 12.73，而行业中位数前瞻市盈率为 19.61。</p>
</div><p>UTHR offers investors upside potential due to its strong sales growth among many of its treatments.</p>
<div class="lb-trans"><p>由于其多种治疗方案的强劲销售增长，UTHR 为投资者提供上涨潜力。</p>
</div><h2><strong>Halozyme Therapeutics</strong>(HALO)</h2>
<div class="lb-trans"><h2><strong>奥洛兹美医疗</strong>（HALO）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Microgen / Shutterstock</p>
<div class="lb-trans"><p>来源：Microgen / Shutterstock</p>
</div><p><strong>Halozyme Therapeutics</strong> (NASDAQ: <strong>HALO</strong>) operates a healthcare tech platform that provides subcutaneous drug delivery solutions along with other commercialized products related to proprietary enzymes.</p>
<div class="lb-trans"><p><strong>奥洛兹美医疗</strong>（纳斯达克股票代码：<strong>HALO</strong>）经营一家提供皮下药物递送解决方案以及其他专有酶相关产品的医疗科技平台。</p>
</div><p>On May 7, Halozyme reported earnings for the first quarter of 2024, stating that total revenue increased by 21% and net income rose by 94%. It also announced a share buyback program with a limit of $750 million in repurchases.</p>
<div class="lb-trans"><p>5 月 7 日，奥洛兹美医疗公布了 2024 年第一季度的财报，称总收入同比增长 21%，净利润增长 94%。它还宣布了一项限额为 7.5 亿美元的股票回购计划。</p>
</div><p>In June, HALO updated its full-year guidance for 2024, stating that expected total revenue is between $935 million and $1,015 million. This update in guidance comes after the patent approval regarding its product Enhanze.</p>
<div class="lb-trans"><p>6 月，HALO 更新了其 2024 年全年指导预期，称预期总收入介于 9.35 亿美元至 10.15 亿美元之间。此次指导更新是在其产品 Enhanze 获得专利批准后发布的。</p>
</div><p>Halozyme is trading at a forward P/E ratio of 13.34, while the sector average is 19.61.</p>
<div class="lb-trans"><p>奥洛兹美医疗的前瞻市盈率为 13.34，而行业平均值为 19.61。</p>
</div><p>HALO would be a great addition to an investment portfolio. It offers growth potential, especially following the recent patent approval and raised guidance.</p>
<div class="lb-trans"><p>HALO 将是投资组合的极佳选择。特别是在最近获得专利批准和提高预期后，它提供了增长潜力。</p>
</div><h2>Amgen (AMGN)</h2>
<div class="lb-trans"><h2>安进（AMGN）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>来源：Shutterstock</p>
</div><p><strong>Amgen</strong> (NASDAQ: <strong>AMGN</strong>) is a therapeutics manufacturer with products such as Enbrel, Otezla, Prolia, Xgeva, and Repatha, which treat a number of issues such as psoriasis, heart attack prevention, and osteoporosis. It also collaborates with other healthcare companies to develop and commercialize treatments.</p>
<div class="lb-trans"><p><strong>安进</strong>（纳斯达克股票代码：<strong>AMGN</strong>）是一家生产治疗方案的制药公司，其产品包括 Enbrel、Otezla、Prolia、Xgeva 和 Repatha，用于治疗诸如牛皮癣、预防心脏病发作和骨质疏松症等多种问题。它还与其他医疗公司合作开发和销售治疗方案。</p>
</div><p>Over this past year, its share price has risen by 47%, partly due to its strong first-quarter earnings report.</p>
<div class="lb-trans"><p>在过去一年中，由于其强劲的第一季度业绩报告，其股价上涨了 47%。</p>
</div><p>On May 2, Amgen reported its earnings for the first quarter of 2024. It stated that total revenue increased by 22%, several of its products reported year-over-year sales growth above double-digits, and its net income remained practically unchanged compared to the year before.</p>
<div class="lb-trans"><p>5 月 2 日，安进公布了 2024 年第一季度的财报。报告显示，总收入增长 22%，其多款产品的年度销售增长超过两位数，净利润与前一年基本持平。</p>
</div><p>Its stock price surged by roughly 12% following its first-quarter earnings report in which it confirmed positive data about its potential weight loss drug MariTide.</p>
<div class="lb-trans"><p>其股价在其关于潜在减肥药物 MariTide 的正面数据的第一季度业绩报告后大约上涨了 12%。</p>
</div><p>Amgen has reported decent sales growth among several treatments, and total revenue for the full year 2024 is expected to be between $32. 5 billion and $33.8 billion. It is a solid choice for investors; it is a robust biotech stock that can offer investors increased returns, especially over the long term.</p>
<div class="lb-trans"><p>安进在多款治疗方案中报告了可观的销售增长，预计 2024 年全年总收入将介于 325 亿美元至 338 亿美元之间。对于投资者来说，它是一个稳健的选择；它是一家强劲的生物科技股票，尤其是从长期来看，可以为投资者带来增加的回报。</p>
</div><p>Amgen is also trading at a decent valuation. Its forward P/E ratio is 16.97, while the sector average is 19.61.</p>
<div class="lb-trans"><p>安进的估值也相当合理。其前瞻市盈率为 16.97，而行业平均值为 19.61。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在发布日期，负责编辑在本文中未持有（直接或间接）任何提到的证券。</em></p>
</div><p><em>As of this writing, Noah Bolton did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>截至目前，Noah Bolton 在本文提到的证券中未持有（直接或间接）任何头寸。本文中表达的观点属于作者个人，遵守 InvestorPlace.com 的发布准则。</em></p>
</div><p>Noah has about a year of freelance writing experience. He’s worked with Investopedia dealing with topics such as the stock market and financial news.</p>
<div class="lb-trans"><p>Noah 拥有约一年的自由撰稿经验。他曾与 Investopedia 合作，涉及股市和财经新闻等主题。</p>
</div><p>Biotech, Healthcare</p>
<div class="lb-trans"><p>生物科技、医疗保健</p>
</div>

第三季度推荐购买的三只生物科技股票